Ceramides: A potential therapeutic target in pulmonary emphysema

Respiratory Research

Volumn 14, Issue 1, 2013, Pages

  Tibboel, Jeroen ^a,c   Reiss, Irwin ^c   de Jongste, Johan C ^c   Post, Martin ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Ceramide; Elastase; Lung function; Sphingolipids

Indexed keywords

ACID; CERAMIDE; DESIPRAMINE; ELASTASE; IMMUNOGLOBULIN M; PROTEIN; SERINE PALMITOYLTRANSFERASE; SPHINGOMYELIN PHOSPHODIESTERASE INHIBITOR; ZOLEDRONIC ACID; ENZYME INHIBITOR; PANCREATIC ELASTASE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; LUNG EMPHYSEMA; LUNG FUNCTION; LUNG LAVAGE; LUNG PARENCHYMA; MACROPHAGE; MORPHOMETRICS; MOUSE; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; LUNG; METABOLISM; PATHOLOGY; UPREGULATION;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CERAMIDES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; LUNG; MICE; MICE, INBRED C57BL; PANCREATIC ELASTASE; PULMONARY EMPHYSEMA; SERINE C-PALMITOYLTRANSFERASE; UP-REGULATION;

EID: 84884742613     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-14-96     Document Type: Article

References (57)

1. Mannino DM. Chronic obstructive pulmonary disease: definition and epidemiology. Respir Care 2003, 48:1185-91. discussion 1191-3.
2. Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007, 4:502-6. 10.1513/pats.200701-001FM, 17878461.
3. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 1995, 152(5 Pt 1):1666-72.
4. Majo J, Ghezzo H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J 2001, 17:946-53. 10.1183/09031936.01.17509460, 11488331.
5. Retamales I, Elliott WM, Meshi B, Coxson HO, Pare PD, Sciurba FC, Rogers RM, Hayashi S, Hogg JC. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001, 164:469-73. 10.1164/ajrccm.164.3.2007149, 11500352.
6. Olivera A, Rivera J. Sphingolipids and the Balancing of Immune Cell Function : Lessons from the Mast Cell. J Immunol 2005, 175:1153-1158.
7. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003, 4:397-407. 10.1038/nrm1103, 12728273.
8. Waeber C, Blondeau N, Salomone S. Vascular sphingosine-1-phosphate S1P1 and S1P3 receptors. Drug News Perspect 2004, 17:365-82. 10.1358/dnp.2004.17.6.829028, 15334188.
9. Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 2005, 5:560-70. 10.1038/nri1650, 15999095.
10. Gulbins E, Li PL. Physiological and pathophysiological aspects of ceramide. Am J Physiol Regul Integr Comp Physiol 2006, 290:R11-26. 10.1152/ajpregu.00416.2005, 16352856.
11. Thon L, Möhlig H, Mathieu S, Lange A, Bulanova E, Winoto-Morbach S, Schütze S, Bulfone-Paus S, Adam D. Ceramide mediates caspase-independent programmed cell death. FASEB J 2005, 19:1945-56. 10.1096/fj.05-3726com, 16319138.
12. Taha TA, Mullen TD, Obeid LM. A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. Biochim Biophys Acta 2006, 1758:2027-36. 10.1016/j.bbamem.2006.10.018, 1766198, 17161984.
13. McVerry BJ, Garcia JGN. Endothelial cell barrier regulation by sphingosine 1-phosphate. J Cell Biochem 2004, 92:1075-85. 10.1002/jcb.20088, 15258893.
14. Becker KA, Riethmuller J, Luth A, Doring G, Kleuser B, Gulbins E. Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am J Respir Cell Mol Biol 2010, 42:716-724. 10.1165/rcmb.2009-0174OC, 19635928.
15. Futerman AH, Hannun YA. The complex life of simple sphingolipids. EMBO Rep 2004, 5:777-82. 10.1038/sj.embor.7400208, 1299119, 15289826.
16. Kolesnick RN, Krönke M. Regulation of ceramide production and apoptosis. Annu Rev Physiol 1998, 60:643-65. 10.1146/annurev.physiol.60.1.643, 9558480.
17. Morita Y, Tilly JL. Sphingolipid regulation of female gonadal cell apoptosis. Ann N Y Acad Sci 2000, 905:209-20.
18. Payne SG, Milstien S, Spiegel S. Sphingosine-1-phosphate: dual messenger functions. FEBS Lett 2002, 531:54-7. 10.1016/S0014-5793(02)03480-4, 12401202.
19. Becker KA, Tummler B, Gulbins E, Grassmé H. Accumulation of ceramide in the trachea and intestine of cystic fibrosis mice causes inflammation and cell death. Biochem Biophys Res Commun 2010, 403:368-374. 10.1016/j.bbrc.2010.11.038, 21078296.
20. Brodlie M, McKean MC, Johnson GE, Gray J, Fisher AJ, Corris PA, Lordan JL, Ward C. Ceramide is increased in the lower airway epithelium of people with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med 2010, 182:369-75. 10.1164/rccm.200905-0799OC, 20395562.
21. Ammit AJ, Hastie AT, Edsall LC, Hoffman RK, Amrani Y, Krymskaya VP, Kane SA, Peters SP, Penn RB, Spiegel S, Panettieri RA. Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma. FASEB J 2001, 15:1212-4.
22. Petrache I, Natarajan V, Zhen L, Medler TR, Richter A, Berdyshev EV, Tuder RM. Ceramide causes pulmonary cell apoptosis and emphysema: a role for sphingolipid homeostasis in the maintenance of alveolar cells. Proc Am Thorac Soc 2006, 3:510. 10.1513/pats.200603-071MS, 16921131.
23. Calabrese F, Giacometti C, Beghe B, Rea F, Loy M, Zuin R, Marulli G, Baraldo S, Saetta M, Valente M. Marked alveolar apoptosis/proliferation imbalance in end-stage emphysema. Respir Res 2005, 6:14. 10.1186/1465-9921-6-14, 549521, 15705190.
24. Sparkman L, Chandru H, Boggaram V. Ceramide decreases surfactant protein B gene expression via downregulation of TTF-1 DNA binding activity. Am J Physiol Lung Cell Mol Physiol 2006, 290:L351-8.
25. Rauvala H, Hallman M. Glycolipid accumulation in bronchoalveolar space in adult respiratory distress syndrome. J Lipid Res 1984, 25:1257-62.
26. Tibboel J, Joza S, Reiss I, Jongste JC D, Post M. Amelioration of hyperoxia-induced lung injury using a sphingolipid-based intervention. Eur Respir J 2013, 42. e-pub ahead of print.
27. Tsuchida S, Engelberts D, Roth M, McKerlie C, Post M, Kavanagh BP. Continuous positive airway pressure causes lung injury in a model of sepsis. Am J Physiol Lung Cell Mol Physiol 2005, 289:L554-64. 10.1152/ajplung.00143.2005, 15923208.
28. Ridsdale R, Roth-Kleiner M, D'Ovidio F, Unger S, Yi M, Keshavjee S, Tanswell AK, Post M. Surfactant palmitoylmyristoylphosphatidylcholine is a marker for alveolar size during disease. Am J Respir Crit Care Med 2005, 172:225-32. 10.1164/rccm.200501-109OC, 15879423.
29. Manwani N, Gagnon S, Post M. Reduced viability of mice with lung epithelial-specific knockout of glucocorticoid receptor. Am J Respir Cell Mol Biol 2010, 43:599-606. 10.1165/rcmb.2009-0263OC, 20042713.
30. Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle GG. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir Res 2006, 10:1-10.
31. Tuder RM, Zhen L, Cho CY, Taraseviciene-Stewart L, Kasahara Y, Salvemini D, Voelkel NF, Flores SC. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol 2003, 29:88-97. 10.1165/rcmb.2002-0228OC, 12600822.
32. Tuder RM, Petrache I, Elias JA, Voelkel NF, Henson PM. Apoptosis and emphysema: the missing link. Am J Respir Cell Mol Biol 2003, 28:551-4. 10.1165/rcmb.F269, 12707010.
33. Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C, Hubbard WC, Berdyshev EV, Tuder RM. Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med 2005, 11:491-498. 10.1038/nm1238, 1352344, 15852018.
34. Plantier L, Marchand-Adam S, Antico VG, Boyer L, De Coster C, Marchal J, Bachoual R, Mailleux A, Boczkowski J, Crestani B. Keratinocyte growth factor protects against elastase-induced pulmonary emphysema in mice. Am J Physiol Lung Cell Mol Physiol 2007, 293:L1230-9. 10.1152/ajplung.00460.2006, 17766584.
35. Sawada M, Ohno Y, La BLB, Funaguchi N, Asai T, Yuhgetsu H, Takemura G, Minatoguchi S, Fujiwara H, Fujiwara T. The Fas/Fas-ligand pathway does not mediate the apoptosis in elastase-induced emphysema in mice. Exp Lung Res 2007, 33:277-88. 10.1080/01902140701509458, 17694438.
36. Lucey EC, Keane J, Kuang P-P, Snider GL, Goldstein RH. Severity of elastase-induced emphysema is decreased in tumor necrosis factor-alpha and interleukin-1beta receptor-deficient mice. Lab Invest 2002, 82:79-85. 10.1038/labinvest.3780397, 11796828.
37. Shigemura N, Sawa Y, Mizuno S, Ono M, Ohta M, Nakamura T, Kaneda Y, Matsuda H. Amelioration of pulmonary emphysema by in vivo gene transfection with hepatocyte growth factor in rats. Circulation 2005, 111:1407-14. 10.1161/01.CIR.0000158433.89103.85, 15781752.
38. Hartmann D, Lucks J, Fuchs S, Schiffmann S, Schreiber Y, Ferreirós N, Merkens J, Marschalek R, Geisslinger G, Grösch S. Long chain ceramides and very long chain ceramides have opposite effects on human breast and colon cancer cell growth. Int J Biochem Cell Biol 2012, 44:620-8. 10.1016/j.biocel.2011.12.019, 22230369.
39. Schweitzer KS, Hatoum H, Brown MB, Gupta M, Justice MJ, Beteck B, Van Demark M, Gu Y, Presson RG, Hubbard WC, Petrache I. Mechanisms of lung endothelial barrier disruption induced by cigarette smoke: role of oxidative stress and ceramides. Am J Physiol Lung Cell Mol Physiol 2011, 301:L836-46. 10.1152/ajplung.00385.2010, 3233827, 21873444.
40. Göggel R, Winoto-Morbach S, Vielhaber G, Imai Y, Lindner K, Brade L, Brade H, Ehlers S, Slutsky AS, Schütze S, Gulbins E, Uhlig S. PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. Nat Med 2004, 10:155-60. 10.1038/nm977, 14704790.
41. Wright JL, Cosio M, Churg A. Animal models of chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 2008, 295:L1-15. 10.1152/ajplung.90200.2008, 2494776, 18456796.
42. Schilling JD, Machkovech HM, He L, Sidhu R, Fujiwara H, Weber K, Ory DS, Schaffer JE. Palmitate and LPS trigger synergistic ceramide production in primary macrophages. J Biol Chem 2012, 288:2923-32.
43. Dechecchi MC, Nicolis E, Mazzi P, Cioffi F, Bezzerri V, Lampronti I, Huang S, Wiszniewski L, Gambari R, Scupoli MT, Berton G, Cabrini G. Modulators of sphingolipid metabolism reduce lung inflammation. Am J Respir Cell Mol Biol 2011, 45:825-33. 10.1165/rcmb.2010-0457OC, 21659660.
44. Cuzzocrea S, Deigner HP, Genovese T, Mazzon E, Esposito E, Crisafulli C, Di Paola R, Bramanti P, Matuschak G, Salvemini D. Inhibition of ceramide biosynthesis ameliorates pathological consequences of spinal cord injury. Shock 2009, 31:635-644.
45. Roth A, Drescher D, Yang Y, Redmer S, Uhlig S, Arenz C. Potent and selective inhibition of acid sphingomyelinase by bisphosphonates. Angew Chem Int Ed 2009, 48:7560-7563.
46. Nakatsuji T, Tang D-CC, Zhang L, Gallo RL, Huang C-M. Propionibacterium acnes CAMP Factor and Host Acid Sphingomyelinase Contribute to Bacterial Virulence: Potential Targets for Inflammatory Acne Treatment. PloS one 2011, 6:e14797. 10.1371/journal.pone.0014797, 3075254, 21533261.
47. Lin W-C, Lin C-F, Chen C-L, Chen C-W, Lin Y-S. Inhibition of Neutrophil Apoptosis via Sphingolipid Signaling in Acute Lung Injury. J Pharmacol Exp Ther 2011, 339:45-53. 10.1124/jpet.111.181560, 21724966.
48. Bäckman U, Svensson A, Christofferson RH, Azarbayjani F. The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res 2008, 28:1551-7.
49. Pewzner-Jung Y, Park H, Laviad EL, Silva LC, Lahiri S, Stiban J, Erez-Roman R, Brügger B, Sachsenheimer T, Wieland F, Prieto M, Merrill AH, Futerman AH. A critical role for ceramide synthase 2 in liver homeostasis: I. alterations in lipid metabolic pathways. J Biol Chem 2010, 285:10902-10. 10.1074/jbc.M109.077594, 2856296, 20110363.
50. Canals D, Perry DM, Jenkins RW, Hannun YA. Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases. Br J Pharmacol 2011, 163:694-712. 10.1111/j.1476-5381.2011.01279.x, 3111673, 21615386.
51. Boggaram V. Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. Clin Sci (Lond) 2009, 116:27-35.
52. De Jong PA, Lindblad A, Rubin L, Hop WCJ, de Jongste JC, Brink M, Tiddens HAWM. Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis. Thorax 2006, 61:80-5. 2080716, 16244089.
53. Sly PD, Brennan S, Gangell C, de Klerk N, Murray C, Mott L, Stick SM, Robinson PJ, Robertson CF, Ranganathan SC. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009, 180:146-52. 10.1164/rccm.200901-0069OC, 19372250.
54. Zhao Z, Zhang H-T, Bootzin E, Millan MJ, O'Donnell JM. Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs. Neuropsychopharmacology 2009, 34:1467-81. 10.1038/npp.2008.183, 2727703, 18923402.
55. Vanbeek E, Löwik C, van der Pluijm G, Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999, 14:722-9. 10.1359/jbmr.1999.14.5.722, 10320520.
56. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296:235-42.
57. Kornhuber J, Tripal P, Reichel M, M\"uhle C, Rhein C, Muehlbacher M, Groemer TW, Gulbins E. Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem 2010, 26:9-20. 10.1159/000315101, 20502000.